Submit Manuscript  

Article Details

Cannabinoid Receptor Antagonists and the Metabolic Syndrome: Novel Promising Therapeutical Approaches

[ Vol. 7 , Issue. 1 ]


C. Cervino, R. Pasquali and U. Pagotto   Pages 21 - 30 ( 10 )


Recent findings in animals and in humans have shown that cannabinoid type 1 receptor antagonists are suitable to become the most promising validated class of drugs to tackle obesity and related disorders. This mini-review will provide a concise and updated revision of the state of art on this topic.


Endocannabinoid, cannabinoid type 1 receptor, cannabinoid type 1 receptor antagonist, rimonabant, metabolic syndrome


Endocrinology Unit and C.R.B.A, Dept. of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, Via Massarenti, 9, 40138 Bologna, Italy.

Read Full-Text article